系统性硬化症中的癌症:EUSTAR注册研究中的临床关联与预后影响
在EUSTAR注册中进行巢式病例对照研究,454例合并癌症的系统性硬化症患者与454例年龄和病程匹配的无癌对照比较。癌症的同步、后续或既往发生与不同血清学和临床特征相关,恶性肿瘤尤其后续发生者显著恶化总生存,提示需分层癌症监测。
要点
- 同步癌症与抗POLR3、U1RNP及吸烟正相关,与指端溃疡负相关。
- 后续肺癌与间质性肺病、抗拓扑异构酶及吸烟相关。
- 恶性肿瘤恶化总生存,后续癌症为死亡主要决定因素。
核心结论
- 癌症发生时机和部位在系统性硬化症中识别出不同的临床-血清学关联,并具有不同预后意义。
- 随访期间诊断的癌症是死亡的主要决定因素,研究结果支持在系统性硬化症中实施分层癌症监测。
研究设计与样本
- 在欧洲硬皮病试验与研究组(EUSTAR)内进行巢式病例对照研究,病例为任何时间点发生癌症的系统性硬化症患者,对照为年龄和病程匹配的无癌患者。
- 共纳入454例合并癌症的系统性硬化症患者和454例对照;平均年龄55±13岁,病程5±2年,88%为女性,27.5%为弥漫型,30.5%有间质性肺病,32%抗拓扑异构酶阳性,10%抗POLR3阳性。
- 癌症按与系统性硬化症发病的时间关系分为同步(±3年)、后续(超过3年后)或既往(超过3年前)。
主要发现
- 454例癌症患者中29%为同步、51%为后续、20%为既往。
- 同步癌症与抗POLR3(OR 2.06,95%CI 1.13-3.69)、U1RNP(OR 3.56,95%CI 1.03-12.3)及吸烟(OR 1.57,95%CI 1.01-2.44)相关,与指端溃疡负相关(OR 0.55,95%CI 0.31-0.93)。
- 钙质沉着与后续癌症负相关(OR 0.42,95%CI 0.17-0.93)。
- 后续肺癌与间质性肺病(OR 2.00,95%CI 1.12-3.54)、抗拓扑异构酶(OR 2.61,95%CI 1.38-5.04)及吸烟相关;乳腺癌与抗POLR3和抗PM/Scl呈时间依赖性关联。
- 接受环磷酰胺治疗的患者癌症发生更频繁;恶性肿瘤恶化总生存,后续癌症尤为明显;放疗未影响死亡率或新发间质性肺病。
临床怎么用
- 对系统性硬化症患者应结合血清学(抗POLR3、U1RNP、抗拓扑异构酶)、吸烟史、间质性肺病及钙质沉着等特征进行分层癌症监测。
- 随访期间新发癌症显著影响生存,需加强后续癌症筛查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Cancer represents a major cause of death in systemic sclerosis (SSc). Established risk factors are limited to specific subsets, particularly early diffuse anti-RNA polymerase III (POLR3)-positive disease, needing further exploration. METHODS: We performed a nested case-control study within the European Scleroderma Trials and Research group: "cases" were defined as patients with SSc who developed cancer at any time point; controls were patients with SSc who were cancer free, matched for age and disease duration. Malignancies were classified as "synchronous" to SSc onset (±3 years), "subsequent" (more than three years after), or "previous" (more than three years before). Clinical, serologic, and treatment associations, as well as survival rates, were analyzed. RESULTS: A total of 454 patients with SSc with cancer (29% synchronous, 51% subsequent, 20% previous) and 454 controls were identified. Mean age was 55 ± 13 years, disease duration was 5 ± 2 years; 88% were female, and 27.5% had diffuse SSc; 30.5% had interstitial lung disease (ILD), 32% had anti-topoisomerase, and 10% had anti-POLR3. Synchronous cancers were associated with anti-POLR3 (odds ratio [OR] 2.06, 95% confidence interval [CI] 1.13-3.69), U1RNP (OR 3.56, 95% CI 1.03-12.3), and smoking (OR 1.57, 95% CI 1.01-2.44), but they were negatively associated with digital ulcers (OR 0.55, 95% CI 0.31-0.93). Calcinosis was inversely associated with subsequent cancers (OR 0.42, 95% CI 0.17-0.93). Breast cancer showed time-dependent associations with anti-POLR3 and anti-PM/Scl; lung cancer was mainly subsequent and associated with ILD (OR 2.00, 95% CI 1.12-3.54), anti-topoisomerase (OR 2.61, 95% CI 1.38-5.04), and smoking. Cancers occurred more frequently in patients treated with cyclophosphamide. Malignancy worsened overall survival, particularly when subsequent. Radiation therapy did not impact mortality rate or new-onset ILD. CONCLUSION: Cancer timing and site identify distinct clinical-serologic associations in SSc, with different prognostic implications. As cancers diagnosed during follow-up are major determinants of death, our findings inform the implementation of stratified cancer surveillance in SSc.
引用
- Tonutti A, Motta F, Moschetti L, et al. Cancer in Systemic Sclerosis: Clinical Associations and Prognostic Impact From the EUSTAR Registry. Arthritis Rheumatol. 2026. PMID: 42663235. doi:10.1002/art.70303
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。